Onkologie. 2014:8(5):201-207

Kidney cancer from the perspective of urologist

Ivan Kolombo, Petr Klézl, Jiří Klečka, Lukáš Bittner, Věra Mašková, Miroslav Hruška, Jindřich Šonský, Petr Nencka, Alexandra Gregušová, Jaroslav Jílek, Tomáš Baitler, Grill Robert
Urologická klinika 3. LF UK a FN Královské Vinohrady, Praha

Renal cell carcinoma (RCC) is the most malignant urological tumour and the incidence of RCC in the Czech Republic is currently highest

in the world. In recent years a new findings in molecular pathophysiology improve our knowledge and ability. Kidney cancer is associated

with seven different genes and is characterized nowadays as metabolic disease. Improved diagnosis and development of new treatment

methods allows much greater individualization of the care. A significant proportion of patients with RCC is still primarily diagnosed in

an advanced stage of disease or progression occurs during the follow up. The basis of the care for patients with RCC is a comprehensive

assessment and treatment, especially surgical or integrating or other minimally invasive ablative techniques in the treatment system.

The review summarizes current trends in therapy and care from the perspective of urologist.

metastasectomy, radiofrequency ablation, targeted therapy, personalized urooncology care.

Keywords: kidney cancer, surgery, minimally invasive treatment, laparoscopy, robotic surgery, vertebroplasty, cementoplasty, embolization,

Published: October 16, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolombo I, Klézl P, Klečka J, Bittner L, Mašková V, Hruška M, et al.. Kidney cancer from the perspective of urologist. Onkologie. 2014;8(5):201-207.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Babjuk M, Matoušková M, Fínek J, Petruželka L, et al. Zhoubné nádory ledvinného parenchymu dospělého věku. In: Konsenzuální doporučené postupy v uroonkologii, Galén Praha 2009: 1-126.
    2. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Uro 2010; 7(5): 277-285. Go to original source... Go to PubMed...
    3. Kolombo I, Hanuš T, Odrážka K, et al. Karcinom ledviny. Mladá Fronta - Aeskulap Praha 2010: 1-279.
    4. Ljungberg B, Bensalah K, Bex A, et al. EAU Guidelines on renal cell carcinoma. European Association of Urology 2014. Available on line: www.uroweb.org.
    5. Weichet J, Vymazal J. Zobrazovací metody (sono, CT, MRI) In: Kolombo I, Hanuš T, Odrážka K et al: Karcinom ledviny. Mladá Fronta - Aeskulap Praha 2010: 83-93.
    6. Kolombo I, Poněšický J, Toběrný M, Kríž R, Zemanová I, et al. Karcinom ledviny v éře nastupujících robotických technologií. Čas. Lék. čes. 2011; 150: 215-222.
    7. Morávek P, Navrátil P, Baše J, et al. Conservative surgery in the treatment of tumours of the renal parenchyma. Ten zdar experience and results. Čas Lék čes 1996; 135: 555-557.
    8. Violette P, Abourbih S, Szymanski KM, et al. Solitary solid renal mass: Can we predict malignancy? BJU Int. 2012; 110: E548-552. Go to original source... Go to PubMed...
    9. Rendon RA, Ross JM, Kirklaand S, et al. A classification tree for the prediction of benign disease in the management of renal masses: Aiding the clinician's thought process. J Urol. 2011; 185: e280-281. Go to original source...
    10. Organ M, Jewett M, Almatar A, et al. External validation and creation of a new classification tree for the prediction of benign versus malignant disease in patients with sall renal masses. J Urol. 2013; 189: e492. Go to original source...
    11. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumours 7 cm or less amenable to partial nephrectomy. J Urol. 2007; 178: 429-434. Go to original source... Go to PubMed...
    12. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized systém for quantitating renal tumor size, location, and depth. J Urol 2009; 182: 844-853. Go to original source... Go to PubMed...
    13. Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurment using the C index method. J Urol 2010; 183: 1708-1713. Go to original source... Go to PubMed...
    14. Ficarra V, Novara G, Secco S, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumors inpatients who are candidates for nephron sparing surgery. Eur Urol 2009; 56: 786-793. Go to original source... Go to PubMed...
    15. Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: A preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011; 60: 241-248. Go to original source... Go to PubMed...
    16. Lebret T, Poulain JE, Molinie V, et al. Percutaneous core biopsy for renal masses: Indications, accuracy and results. J Urol. 2007; 178: 1184-1188. Go to original source... Go to PubMed...
    17. Kolombo I, Kolombová J, et al. Mezioborová spolupráce v urologii. Urolog. pro Praxi, 2007; 8(6): 262-267.
    18. Rendon RA, Kapoor A, Breau R, Leveridge M, Feifer A, Black PC, et al. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J 2014; 8(5-6): e398-412. Go to original source... Go to PubMed...
    19. Leveridge MJ, Finelli A, Kachura JR, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011; 60: 578-584. Go to original source... Go to PubMed...
    20. Mullins JK, Rodriguez R. Renal cell carcinoma seeding of a percutaneous biopsy tract. Can Urol Assoc J. 2013; 7: E176-179. Go to original source... Go to PubMed...
    21. Boorjian S. Commentary on "Long-term survival following partial vs. radical nephrectomy among older patients with early-stage kidney cancer." Tan HJ, Norton, EC, Ye Z, Hafez KS, Gore JL, Miller DC, Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI: JAMA 2012;307 (15): 1629-35. Urol Oncol. 2013; 31: 126-127. Go to original source... Go to PubMed...
    22. Russo P. Oncological and renal medical importance of kidney-sparing surgery. Nat Rev Urol. 2013; 10: 292-299. Go to original source... Go to PubMed...
    23. Thompson RH, Kaag M, Vickers A, et al. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol. 2009; 181: 993-997. Go to original source... Go to PubMed...
    24. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011; 59: 543-552. Go to original source... Go to PubMed...
    25. Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol. 2010; 183: 1317. Go to original source... Go to PubMed...
    26. Kates M, Badalato GM, Pitman M, et al. Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less. J Urol. 2011; 186: 1247-1253. Go to original source... Go to PubMed...
    27. Abouassaly R, Finelli A, Tomlinson GA, et al. How often are patients with diabetes or hypertension being treated with partial nephrectomy for renal cell carcinoma? A population-based analysis. BJU Int. 2011; 108: 1806-1812. Go to original source... Go to PubMed...
    28. Sun M, Bianchi M, Hansen J, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol. 2012; 62: 696-703. Go to original source... Go to PubMed...
    29. Colli J, Sartor O, Grossman L, et al. Underutilization of partial nephrectomy for stage t1 renal cell carcinoma in the United States, trends from 2000 to 2008. A long way to go. Clin Genitourin Cancer. 2012; 10: 219-224. Go to original source... Go to PubMed...
    30. Minervini A, Serni S, Tuccio A, et al. Simple enucleation versus radical nephrectomy in the treatment of pT1a and pT1b renal cell carcinoma. Ann Surg Oncol. 2012; 19:694-700. Go to original source... Go to PubMed...
    31. Kolombo I, Poněšický J, Toběrný M, Kríž R, Zemanová I, Weichet J, Vymazal J, et al. Karcinom ledviny v éře nastupujících robotických technologií. Čas. Lék. čes. 2011; 150: 215-222.
    32. Schmidt M, Chocholatý M, Veselý Š, Jarolím L, Babjuk M. Laparoscopic partial nephrectomy: evaluation of clampless technique. European Urology Suppl. 10, 9, 2011: 653. Go to original source... Go to PubMed...
    33. Thomas AZ, Smyth L, Hennessey D, et al. Zero ischemia laparoscopic partial thulium laser nephrectomy. J Endourol. 2013; 27: 1366-1370. Go to original source... Go to PubMed...
    34. Gill IS, Patil MB, Abreu AL, et al. Zero ischemia anatomical partial nephrectomy: a novel approach. J Urol. 2012; 187: 807-814. Go to original source... Go to PubMed...
    35. Borofsky MS, Gill IS, Hemal AK, et al. Near-infrared fluorescence imaging to facilitate super-selective arterial clamping during zero-ischaemia robotic partial nephrectomy. BJU Int. 2013; 111: 604-610. Go to original source... Go to PubMed...
    36. Wang AJ, Bhayani SB. Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: Single-surgeon analysis of >100 consecutive procedures. Urology. 2009; 73: 306-310. Go to original source... Go to PubMed...
    37. Bensalah K, Pantuck AJ, Rioux-Leclercq N, et al. Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing. Surgery. Eur Urol 2010; 57: 466-473. Go to original source... Go to PubMed...
    38. Raz O, Mendlovic S, Shilo Y, et al. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery. Urology. 2010; 75: 277-280. Go to original source... Go to PubMed...
    39. AnI, Finelli A, Alibhai SMH, et al. Prevalence and impact on survival of positive surgical margins in partial nephrectomy for renal cell carcinoma: a population-based study. BJU Int. 2013; 111: E300-E305. Go to original source... Go to PubMed...
    40. Sundaram V, Figenshau RS, Roytman TM, et al. Positive margin during partial nephrectomy: does cancer remain in the renal remnant? Urology.2011; 77: 1400-1403. Go to original source... Go to PubMed...
    41. Herold I, Sittová N, Čurdová M, Kolombo I, Pabišta R, Adamus M. Anesteziologické aspekty ireverzibilní elektroporace karcinomu prostaty: antagonizace nervosvalové blokády sugammadexem vs. neostigminem - retrospektivní studie. Anest. intenziv. Med. 2013; 24(4): 230-236.
    42. Kolombo I, Kříž R, Janoušková L, Poněšický J, Beňo P, et al. Selective embolization and radiofrequency ablation of renal mass in polymorbid and elderly patients - our experience. European Urology Suppl 2007: 26. Go to PubMed...
    43. Kříž R, Vymazal J. Miniinvazivní léčba pod kontrolou zobrazovacích metod. In: Kolombo I, Hanuš T, Odrážka K et al: Karcinom ledviny. Mladá Fronta - Aeskulap Praha 2010: 140-148.
    44. Janík V, Laboš M, Kachlířová Z, Klézl P. Embolizace - metoda léčby iatrogenních a traumatických krvácivých komplikací ledvin. Ces Radiol 2012; 66(3): 317-336: Abstr 332. Go to original source...
    45. Fiala R, Všetička J. Laparoskopická ručně asistovaná resekce ledvin za využití radiofrekvenční koagulace. Ces Urol 2008; 12(2): 117, Abstract 60.
    46. Čermák A, Pacík D. Minimálně invazivní ablační techniky při léčbě malých renálních tumorů. Urol List 2012; 10(3): 16-23.
    47. Hora M, Klečka J jr., Hes O, Ferda J, Ürge T. Miniinvazivní laparoskopická či retroperitoneoskopická radikální nefrektomie pro parenchymový tumor Rozhl. Chir., 2005; 84(5): 246-252. Go to PubMed...
    48. Šafařík L, Novák K, Sedláček J, Macek P, Pešl M, Sobotka R, Dvořaček J. Rozvoj laparoskopické operatívy dospělých na Urologicke klinice 1. LF a VFN v Praze. Čas Lek čes 2007; 146(10): 806-808.
    49. Kletscher BA, Qian J, Bostwick DG, et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol. 1996; 155: 1844-1846. Go to original source... Go to PubMed...
    50. Canfield SE, Kamat AM, Sanchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): The impact of aggressive surgical resection on patient outcome. J Urol. 2006; 175: 864-869. Go to original source... Go to PubMed...
    51. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003; 169: 2076-2083. Go to original source... Go to PubMed...
    52. Leveridge MJ, Jewett MA. Recent developments in kidney cancer. Can Urol Assoc J. 2011; 5: 195-203. Go to original source... Go to PubMed...
    53. Capitanio, R. Matloob, N. Suardi, et al. The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma. Urologia 2012; 79(2): 109-115. Go to original source... Go to PubMed...
    54. Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011; 60 (6): 1212-20. Go to original source... Go to PubMed...
    55. Hurtová M, Louda M, Romžová M, Broďák M. Bilaterální karcinom ledviny řešený jednodobou operací, nefrektomií a resekcí ledviny. Ces Urol 2012; 16(2): 117-120.
    56. Eret V, Hora M, Ferda J, Chudáček Z, Hes O, Ürge T, Klečka J. Nejnovější metodiky v chirurgické léčbě nádorů ledvin. Ces Urol 2009; 13(1): 24-25.
    57. Schmidt M, Veselý Š, Dušek P, Jarolím L, Babjuk M. Laparoskopická nefrektomie. Česká urologie 2011; 15(Suppl. 1): 59-60.
    58. Kaouk JH, Goel RK. Single-port laparoscopic and robotic partial nephrectomy. Eur Urol 2009; 55: 1163-1170. Go to original source... Go to PubMed...
    59. Kolombo I, Poněšický J, Poršová M, Pabišta R, Porš J, et al. Pokročilý karcinom ledviny - současné trendy terapie (1. část). Urolog. pro Praxi 2009; 10(3): 182-189.
    60. Boorjian SA, Sengupta S, Blute ML. Renal cell carcinoma: Vena caval involvement. BJU Int. 2007; 99: 1239-1244. Go to original source... Go to PubMed...
    61. Kolombo I, Poněšický J, Poršová M, Pabišta R, Porš J, et al: Pokročilý karcinom ledviny - současné trendy terapie (2. část). Urolog. pro Praxi 2009; 10(4): 218-230.
    62. Granberg CF, Boorjian SA, Schaff HV, et al. Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumour thrombectomy facilitated by vascular bypass. Urology. 2008; 72: 148-152. Go to original source... Go to PubMed...
    63. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011; 16(Suppl 2): 45-50. Go to original source... Go to PubMed...
    64. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011; 185: 60-66. Go to original source... Go to PubMed...
    65. Hoang AN, Vaporcyian AA, Matin SF. Laparoscopy-assisted radical nephrectomy with inferior vena caval thrombectomy for level II to III tumour thrombus: A single-institution experience and review of the literature. J Endourol. 2010; 24: 1005-1012. Go to original source... Go to PubMed...
    66. Morávek P. Nádory ledvin a horních močových cest. Chirurgická terapie. In: Dvořáček J, Babjuk M, et al. Onkourologie. Galén a Karolinum 2005: 44-56.
    67. Barocas DA, Chang SS. The role of cytoreductive nephrectomy in the era of targeted therapy. AUA News 2008; 13(10): 1-6.
    68. Zachoval R, Urban M, Heráček J, et al. Současný pohled na metastazující karcinom ledviny z hlediska přežití v závislosti na druhu terapie. Urologie pro praxi 2003; 5: 190-192.
    69. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 2007 Jun; 177(6): 1978-1984. Go to original source... Go to PubMed...
    70. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon ?-2b compared with interferon ?-2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345: 1655-1659. Go to original source... Go to PubMed...
    71. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon ?-based immunotherapy compared with interferon ? alone for metastatic renal cell carcinoma: a randomized trial. Lancet 2001; 358: 966-970. Go to original source... Go to PubMed...
    72. Russo P, Synder M, Vickers A, et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. Scientific Journal 2007; 7: 768. Go to original source... Go to PubMed...
    73. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007; 356: 115-124. Go to original source... Go to PubMed...
    74. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon alfa (IFN-) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol, suppl 2007; 25: abstract 5024. Go to original source...
    75. Margulis V, Martin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurent renal cell carcinoma. J Urol 2008; 180: 94-98. Go to original source... Go to PubMed...
    76. Kawaciuk I. Prognóza karcinomu ledviny. Galén Praha 2006: 1-248.
    77. Kolombo I, Chrobok J, Poněšický J, et al. Our first experience with replacement for vertebral body by Synex(R) device for spine metastatic disease of urooncological patients. European Urology Suppl 2007: 98. Go to PubMed...
    78. Ruutu M, Bono P, Taari K. Resection of renal cell cancer metastases: Where do we stand in 2008? Eur Urol Suppl 2008; 7(5): 436-442. Go to original source...
    79. Kolombo I, Kolombová J, Dvořáček J, Hanuš T, et al. Skeletální postižení v uroonkologii, Galén Praha 2005.
    80. Jarolím J, Abrahámová, J, Buncová M, Foldyna M, Kolombo I, Matoušková M, Mechl Z, Repko M. Kostní metastázy. Program urologie a onkologie Elektronické Univerzity. 2007 www.euni.cz.
    81. Sengupta S, Leibovich B, Blute M, et al. Surgery for metastatic renal cell cancer. J Urol 2005; 23: 155. Go to original source... Go to PubMed...
    82. Kolombo I, Kříž R, Vymazal J, Poněšický J, Weichet J, et al. Karcinom ledviny - současná situace a integrace miniinvazivních technik (vertebroplastiky, cementoplastiky, selektivní embolizace a radiofrekvenční ablace), biologické a konvenční chirurgické léčby. Urolog. pro Praxi 2011; 12(2): 80-90.
    83. Sachs DC, Inamasu J, Mendel EE, Guiot BH. Transoral vertebroplasty for renal cell metastasis involving the axis: case report. Spine 2006; 31(24): E925-E928. Go to original source... Go to PubMed...
    84. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008 Oct 1; 113(7): 1641-1648. Go to original source... Go to PubMed...
    85. Šimonová G, Liščák R. Mozkové metastázy karcinomu ledviny a jejich léčba. In: Kolombo I, Hanuš T, Odrážka K et al: Karcinom ledviny. Mladá Fronta - Aeskulap Praha 2010: 231-241.
    86. Petruželka L, Babjuk M, et al. Léčba metastatických nádorů ledvin. Galén Praha 2011: 1-102.
    87. Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102: 692-696. Go to original source... Go to PubMed...
    88. Mukund A, Gamanagatti S. Ethanol ablation of renal cell carcinoma for palliation of symptoms in advanced disease. J Palliat Med. Feb 2010; 13(2): 117-120. Go to original source... Go to PubMed...
    89. Šlampa P, Hynková L, Zitterbartová J. Radioterapie karcinomu ledviny. Farmakoterapie 2010; 6(1): 28-32.
    90. Jewett MA, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: Progression patterns of early stage kidney cancer. Eur Urol. 2011; 60: 39-44. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.